Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02416622 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

A Phase 1 study of X-linked Retinoschisis, sponsored by Beacon Therapeutics.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
9
Study locations

NCT02416622 is a Phase 1 study of X-linked Retinoschisis that has completed, run by Beacon Therapeutics. The registered enrollment target is 27 participants. The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02416622, a Phase 1 study of X-linked Retinoschisis, has completed, sponsored by Beacon Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
9
Study locations

Study Summary

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.

Conditions Studied

Interventions

  • BIOLOGICAL rAAV2tYF-CB-hRS1

Study Locations (9)

Texas

  • Retina Foundation of the Southwest - Dallas
  • Baylor College of Medicine, Alkek Eye Center - Houston

California

  • University of California San Francisco, Dept. of Ophthalmology - San Francisco

Florida

  • University of Miami - Miller School of Medicine Bascom Palmer Eye Institute - Miami

Maryland

  • The Wilmer Eye Institute, Johns Hopkins Hospital - Baltimore

Massachusetts

  • Massachusetts Eye and Ear Infirmary - Boston

Michigan

  • University of Michigan Kellogg Eye Center - Ann Arbor

North Carolina

  • Duke Eye Center, Duke University Medical Center - Durham

Oregon

  • Casey Eye Institute, Oregon Health and Sciences University - Portland

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2015-05
Est. Completion 2023-05-09
Phase Phase 1

Sponsor

Beacon Therapeutics

12 total trials

What the Registry Record Tells You About NCT02416622

The ClinicalTrials.gov registry entry for NCT02416622 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beacon Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with X-linked Retinoschisis appearing as the primary indexed condition, and to 1 intervention - of which rAAV2tYF-CB-hRS1 is the first listed.

NCT02416622 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT02416622 about?

NCT02416622 is a clinical study titled "Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)". This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.

What is the current status of trial NCT02416622?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-05. Estimated completion is 2023-05-09.

What conditions does trial NCT02416622 study?

This clinical trial studies the following conditions: X-linked Retinoschisis.

What interventions are being tested in trial NCT02416622?

The interventions under investigation include: rAAV2tYF-CB-hRS1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02416622?

This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02416622 being conducted?

This trial has 9 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for X-linked Retinoschisis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.